Glutathione Benefits: What Studies Report

Glutathione is a tripeptide (glutamate, cysteine, glycine) that the body synthesizes and that has also been studied as an oral, topical, intravenous and precursor-delivered supplement. Because it is sold and discussed under many different headings, the published evidence is uneven: some outcome domains have randomized placebo-controlled trials, others have only narrative reviews, animal work, or nothing at all. This page groups what researchers actually measured and reported, names the study type, and links each finding to PubMed in the same passage. Background on the molecule itself is covered on the glutathione overview.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here describes a protocol, and no outcome is presented as certain.

Outcome domains at a glance

Skin pigmentation and melasma

This is the most heavily published clinical domain. A randomized, double-blind, placebo-controlled study of oral glutathione as a whitening agent compared 500 mg daily with placebo over four weeks and the researchers reported lower melanin index readings in the glutathione arm than in placebo (PMID 20524875). That trial was small and short, which limits how far its findings extend.

Reviews have repeatedly returned to the same question. A 2016 review in the Indian Journal of Dermatology, Venereology and Leprology examined glutathione as a skin whitening agent under the explicit headings of facts, myths, evidence and controversies (PMID 27088927), and a 2017 review summarized the proposed antiaging and antimelanogenic effects of glutathione (PMID 28490897). A 2019 systematic review in the Journal of Cosmetic Dermatology assessed the clinical effect of glutathione on skin color and other related skin conditions (PMID 30895708), and a 2025 systematic review in the International Journal of Dermatology addressed glutathione as a skin-lightening agent and its use in melasma specifically (PMID 39444151).

A 2025 narrative review in Cureus explored both safety and efficacy of glutathione supplementation for skin lightening (PMID 40013212). Taken together, the existence of multiple reviews across nearly a decade — several of which are framed around controversy rather than consensus (PMID 27088927) — indicates an evidence base that remains contested rather than settled, with small trials, differing routes of administration and short follow-up periods.

Routes of administration matter in this literature

Oral, topical, intraoral and intravenous glutathione have all been discussed in the skin-lightening reviews, and safety questions attached to injectable use are part of why the 2016 review was organized around myths and controversies (PMID 27088927). The 2025 narrative review likewise paired safety with efficacy rather than treating efficacy alone (PMID 40013212). Readers comparing studies should note which route each one tested, because results from one route do not transfer to another.

Does oral glutathione raise body glutathione levels?

This question has its own dedicated trial. A randomized controlled trial published in the European Journal of Nutrition tested oral glutathione supplementation at 250 mg and 1,000 mg daily for six months against placebo and measured body stores of glutathione (PMID 24791752). The researchers reported increases in body glutathione stores with supplementation, which is a biomarker outcome — it describes a measured change in tissue and blood glutathione, not a clinical benefit such as reduced disease risk.

The distinction matters. A supplement can move a laboratory marker without any demonstrated downstream effect on symptoms, function or disease, and the trial described above was designed to answer the store-level question rather than a clinical endpoint (PMID 24791752).

Aging, oxidative stress and mitochondrial function: precursor trials

Rather than supplying glutathione directly, several investigators have supplied its amino acid precursors. A randomized clinical trial in older adults tested supplementation with glycine and N-acetylcysteine (GlyNAC) and reported improvements in glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function and hallmarks of aging (PMID 35975308). That trial was published in The Journals of Gerontology Series A in 2023 and is the most frequently cited human study for the "glutathione and aging" claim.

Two cautions accompany it. First, the intervention was a precursor combination, not glutathione itself, so its results describe GlyNAC rather than oral glutathione (PMID 35975308). Second, the outcomes spanned many domains at once, and multi-outcome trials in older adults require independent replication before their findings can be generalized. The separate oral glutathione trial measured stores only and did not test aging outcomes (PMID 24791752).

Related precursor and redox research in other conditions

Because N-acetylcysteine is a cysteine donor for glutathione synthesis, NAC trials are often cited in discussions of glutathione benefits. A meta-analysis of randomized controlled trials examined the effectiveness of N-acetylcysteine in autism spectrum disorders (PMID 32900213), and a randomized, double-blind, placebo-controlled trial evaluated N-acetylcysteine as an adjuvant treatment for alcohol use disorder (PMID 41021585). These studies tested NAC as the intervention; they do not establish anything about supplemental glutathione, and they are listed here only because they are commonly folded into glutathione marketing narratives.

The same applies to selenium, a cofactor for glutathione peroxidase enzymes. A prospective randomized controlled trial studied the effect of selenium on thyroid autoimmunity and regulatory T cells in patients with Hashimoto's thyroiditis (PMID 33650299). That trial's intervention was selenium, not glutathione, and its outcomes were immunological markers in an autoimmune thyroid population.

Animal evidence

Labelled animal data. A veterinary study in healthy dogs assessed the safety and efficacy of a ribose-cysteine supplement for increasing erythrocyte glutathione concentration (PMID 34296936). Findings in dogs do not transfer to humans, and the outcome measured was a red-cell biomarker rather than a clinical endpoint.

Claims with weak or absent evidence in this citation set

Several popular claims are not supported by any of the verified studies covered here, and saying so plainly is more useful than filling the gap with speculation:

• "Detoxification" or liver cleansing. None of the trials cited on this page measured a detoxification endpoint; the oral supplementation RCT measured body glutathione stores only (PMID 24791752).
• Immune enhancement. The immunological outcomes in this set came from a selenium trial in Hashimoto's thyroiditis, not from glutathione supplementation (PMID 33650299).
• Fat loss, athletic performance, hair growth. No study in this citation set measured body composition, exercise performance or hair outcomes; the physical function findings reported came from a glycine plus N-acetylcysteine trial in older adults (PMID 35975308).
• Permanent or whole-body skin lightening. The randomized trial in this area ran four weeks at 500 mg daily and measured melanin index (PMID 20524875), and reviews have continued to frame the field in terms of unresolved controversy (PMID 27088927, PMID 39444151).

Safety and tolerability: What Studies Report

Safety has been addressed most directly in the dermatology literature. A 2025 narrative review in Cureus was constructed specifically to explore the safety as well as the efficacy of glutathione supplementation for skin lightening (PMID 40013212), and the 2016 review catalogued controversies surrounding its cosmetic use (PMID 27088927). In the supplementation setting, the six-month randomized controlled trial of oral glutathione at 250 mg and 1,000 mg daily was conducted in healthy adults and reported on body glutathione stores as its primary measure (PMID 24791752). Long-term safety data in the general population remain limited, and the veterinary safety assessment of a ribose-cysteine supplement applies to dogs only (PMID 34296936).

How to read this evidence

1. Check the molecule. Trials of GlyNAC (PMID 35975308), N-acetylcysteine (PMID 32900213) and selenium (PMID 33650299) are frequently cited as glutathione evidence but tested different compounds.
2. Check the endpoint. Melanin index (PMID 20524875) and erythrocyte glutathione (PMID 34296936) are biomarkers, not patient-reported outcomes.
3. Check the duration. Four weeks (PMID 20524875) and six months (PMID 24791752) answer very different questions.
4. Check the species. Dog data are dog data (PMID 34296936).

Across the domains above, the pattern the published record shows is a small number of short randomized trials, a larger number of reviews revisiting the same limited trial pool (PMID 30895708, PMID 39444151), and precursor studies that are often quoted as though they were glutathione studies (PMID 35975308). Again, this page is educational only and is not medical advice; decisions about any supplement belong with a licensed physician.

References

• Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial (The Journals of Gerontology Series A, 2023)
• Glutathione as a skin whitening agent: Facts, myths, evidence and controversies (Indian Journal of Dermatology, Venereology and Leprology, 2016)
• Glutathione as a skin-lightening agent and in melasma: a systematic review (International Journal of Dermatology, 2025)
• Glutathione and its antiaging and antimelanogenic effects (Clinical, Cosmetic and Investigational Dermatology, 2017)
• Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study (The Journal of Dermatological Treatment, 2012)
• Randomized controlled trial of oral glutathione supplementation on body stores of glutathione (European Journal of Nutrition, 2015)
• Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review (Cureus, 2025)
• Effectiveness of N-acetylcysteine in autism spectrum disorders: A meta-analysis of randomized controlled trials (The Australian and New Zealand Journal of Psychiatry, 2021)
• Effect of selenium on thyroid autoimmunity and regulatory T cells in patients with Hashimoto's thyroiditis: A prospective randomized-controlled trial (Clinical and Translational Science, 2021)
• Safety and efficacy of a ribose-cysteine supplement to increase erythrocyte glutathione concentration in healthy dogs (American Journal of Veterinary Research, 2021)
• The clinical effect of glutathione on skin color and other related skin conditions: A systematic review (Journal of Cosmetic Dermatology, 2019)
• A randomized, double-blind, placebo-controlled trial of N-acetylcysteine as an adjuvant treatment for alcohol use disorder (Revista Brasileira de Psiquiatria, 2025)